HUBEI PROVINCE, China--(BUSINESS WIRE)--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTC BB: BPMA), a China-based pharmaceutical company producing both Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, announced today it realized a total of $3.3 MM in revenue through December 2007 from the previously reported $3.8 MM in combined Gendicine® orders generated at China’s September 2007 national biotechnology conference.

In realizing revenue already equal to 87% of the original combined orders, Benda is $300,000 ahead of schedule – the Company previously indicated that it could realize $3.0 MM by the end of 2007.

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer.